46 search results for: CRSwNP
ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?
Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.
Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?
This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
Compounded Burden of Co-existing Type 2 Airway Diseases
In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?
Prof. Hellings and Prof. Corso explore the time frame to assess if the patient with CRSwNP has achieved remission
What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?
Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP
IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
Global CRSwNP Awareness Day 2024
Explore resources on the importance of partnering with patients to empower them to take an active role in their care.
